NO20030337L - Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber - Google Patents

Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber

Info

Publication number
NO20030337L
NO20030337L NO20030337A NO20030337A NO20030337L NO 20030337 L NO20030337 L NO 20030337L NO 20030337 A NO20030337 A NO 20030337A NO 20030337 A NO20030337 A NO 20030337A NO 20030337 L NO20030337 L NO 20030337L
Authority
NO
Norway
Prior art keywords
eyes
treatment
respiratory tract
hoyfever
rutosides
Prior art date
Application number
NO20030337A
Other languages
English (en)
Other versions
NO20030337D0 (no
Inventor
Kurt Frimann Berg
Original Assignee
Immupharm Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immupharm Aps filed Critical Immupharm Aps
Publication of NO20030337D0 publication Critical patent/NO20030337D0/no
Publication of NO20030337L publication Critical patent/NO20030337L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20030337A 2000-07-28 2003-01-22 Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber NO20030337L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200001152 2000-07-28
DKPA200001316 2000-09-04
DKPA200001935 2000-12-23
DKPA200100007 2001-01-03
DKPA200100827 2001-05-22
PCT/DK2001/000515 WO2002009699A2 (en) 2000-07-28 2001-07-23 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract

Publications (2)

Publication Number Publication Date
NO20030337D0 NO20030337D0 (no) 2003-01-22
NO20030337L true NO20030337L (no) 2003-03-21

Family

ID=27512989

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030337A NO20030337L (no) 2000-07-28 2003-01-22 Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber

Country Status (20)

Country Link
US (2) US7166640B2 (no)
EP (1) EP1307189B1 (no)
JP (1) JP2004505046A (no)
KR (1) KR100824075B1 (no)
CN (1) CN100411617C (no)
AT (1) ATE325612T1 (no)
AU (2) AU2001279587B2 (no)
BR (1) BR0112818A (no)
CA (1) CA2416899C (no)
DE (1) DE60119534T2 (no)
DK (1) DK1307189T3 (no)
EA (1) EA008612B1 (no)
ES (1) ES2263643T3 (no)
HK (1) HK1057330A1 (no)
IL (2) IL154144A0 (no)
MX (1) MXPA03000848A (no)
NO (1) NO20030337L (no)
NZ (1) NZ524121A (no)
PL (1) PL203216B1 (no)
WO (1) WO2002009699A2 (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10122714A1 (de) * 2001-05-10 2002-11-21 Brench Ag Verwendung von Rutinen und Aescinen zur Behandlung okulärer Durchblutungsstörungen
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US8945518B2 (en) 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
AU2003228777C1 (en) 2002-04-30 2009-08-13 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
FR2845597B1 (fr) * 2002-10-11 2005-03-11 Innothera Lab Sa Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer
CN1717227A (zh) 2002-10-24 2006-01-04 伊穆法姆公司 含类黄酮和薄荷醇的药物组合物
EP1591123B1 (en) * 2003-01-21 2009-08-19 Su, Wei-wei Uses of naringenin, naringin and salts thereof as expectorants in the treatment of cough, and compositions thereof
EP1631304A4 (en) 2003-04-04 2007-03-21 Unigen Pharmaceuticals Inc FORMULATION FOR INHIBITING CYCLOOXYGENASE (COX) AND LIPOXYGENASE (LOX) FOR SKIN CARE
US7332475B2 (en) * 2003-07-22 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Preventive or therapeutic composition for viral infectious disease
DE10361444A1 (de) * 2003-12-23 2005-07-21 Axaron Bioscience Ag Verfahren zur in vitro Differenzierung neuronaler Stammzellen oder von neuronalen Stammzellen abgeleiteter Zellen
RU2383353C2 (ru) 2004-04-28 2010-03-10 Хатчисон Медифарма Энтерпрайзис Лимитед Суммарные экстракты из andrographis paniculata
WO2006017505A2 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
TW200630102A (en) * 2004-10-19 2006-09-01 Unigen Pharmaceuticals Inc Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
EP1843782A1 (en) * 2005-02-04 2007-10-17 ViraNative AB Method and use of interferon compositions for the treatment of avian influenza
RU2431634C2 (ru) * 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
PL1976532T3 (pl) * 2006-01-27 2016-05-31 Univ Yale Szybko działający inhibitor wydzielania kwasu żołądkowego
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
CN101405015B (zh) * 2006-03-24 2015-04-01 乔治斯·潘达利斯 用于预防和治疗普通感冒病的组合物
JPWO2007125731A1 (ja) * 2006-04-28 2009-09-10 株式会社メニコン ソフトコンタクトレンズ用溶液及びそれを用いて得られる薬剤徐放性ソフトコンタクトレンズ並びにその製造方法
KR100792626B1 (ko) * 2006-05-30 2008-01-09 프로테온 주식회사 카테킨 유도체 화합물을 유효성분으로 하는 독감 바이러스감염성 질환 예방 및 치료제
KR100770746B1 (ko) * 2006-06-15 2007-10-30 제주대학교 산학협력단 항염활성을 갖는 감귤 유래 노빌레틴과 그 분리.정제방법
US8846757B2 (en) 2006-07-31 2014-09-30 The Trustees Of Columbia University In The City Of New York Bioactive depside and anthocyanin compounds, compositions, and methods of use
RU2315593C1 (ru) * 2006-08-02 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Липосомальная композиция антиоксидантов для ингаляций при заболеваниях легких и верхних дыхательных путей
US8465782B2 (en) * 2006-09-21 2013-06-18 Immune Guard, LLC Methods and materials for reducing risk of cold and/or flu
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
EA015930B1 (ru) 2006-12-05 2011-12-30 Мариномед Биотехнологи Гмбх Применение йота-каррагинана для лечения риновирусной инфекции и фармацевтическая композиция для лечения риновирусной инфекции, содержащая йота-каррагинан
WO2008106979A2 (en) * 2007-03-02 2008-09-12 Immupharm A/S Pharmaceutical compositions comprising flavonoids and xylitol
KR100853442B1 (ko) * 2007-08-21 2008-08-21 프로테온 주식회사 카테킨 유도체 화합물을 유효성분으로 하는 독감 바이러스감염성 질환 예방용 건강식품
US20090117209A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract
KR100999872B1 (ko) * 2008-06-12 2010-12-09 한국생명공학연구원 홍경천 추출물, 홍경천 분획물, 이로부터 분리한플라보노이드계 화합물, 이의 유도체 화합물 또는 이의약학적으로 허용 가능한 염을 유효성분으로 함유하는바이러스 질환의 예방 및 치료용 약학적 조성물
WO2009151173A1 (en) * 2008-06-12 2009-12-17 Korea Research Institute Of Bioscience And Biotechnology Pharmaceutical compositions for prevention and treatment of viral diseases containing rhodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient
US20100009012A1 (en) * 2008-07-11 2010-01-14 Zukkoor N David Chewable pharyngeal inflammation symptom relief composition
US20150005325A1 (en) * 2009-06-16 2015-01-01 Biocopea Limited Drug Combinations and Uses in Treating a Coughing Condition
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
JP5617097B2 (ja) * 2010-05-13 2014-11-05 敏彦 四宮 亜鉛錯体とプロスタグランジン等からなる外用剤
JP5781606B2 (ja) 2010-06-16 2015-09-24 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
CN101891783B (zh) * 2010-06-23 2013-04-03 四川大学 黄酮-金属络合微球及其制备方法与应用
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
CN102048726A (zh) * 2011-01-10 2011-05-11 华东理工大学 川陈皮素的应用
WO2012136851A1 (en) * 2011-04-08 2012-10-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
WO2014010718A1 (ja) 2012-07-13 2014-01-16 株式会社新日本科学 キラル核酸アジュバント
EP3308835B1 (en) 2013-03-13 2020-01-01 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN105263579B (zh) 2013-03-13 2020-01-10 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗血管炎中的用途
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3037132B1 (en) * 2014-12-23 2018-10-31 Farma-Derma S.R.L. Zinc salt and polyphenol composition
DE102015115876A1 (de) * 2015-09-21 2017-03-23 Eberhard Karls Universität Tübingen Medizinische Fakultät Substanz zur Prophylaxe und Behandlung von Infektionen durch Influenzaviren
CN105461676B (zh) * 2015-11-20 2017-12-12 上海秉丰生物科技有限公司 一种伪麻黄碱类衍生物及其制备方法与应用
WO2017147540A1 (en) * 2016-02-25 2017-08-31 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN106265630A (zh) * 2016-10-13 2017-01-04 吉林大学 穗花杉双黄酮在研发治疗肺炎药物中的应用
FR3057773B1 (fr) 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
CA3041644C (en) * 2016-10-24 2020-03-10 Colgate-Palmolive Company Oral care compositions and methods of use
CN106667996B (zh) * 2017-02-27 2019-04-09 吉林大学 桑色素在制备抗猪链球菌病药物中的应用
CN106667997A (zh) * 2017-02-27 2017-05-17 吉林大学 表没食子儿茶素没食子酸酯抑制肺炎链球菌致病力及应用
CN108484751B (zh) * 2018-04-19 2020-06-23 西南大学 川陈皮素抗原及其制备方法与应用
CN108704074A (zh) * 2018-06-27 2018-10-26 陶燃 一种治疗慢性鼻炎的药物组合物及其应用
US11304968B2 (en) 2018-11-16 2022-04-19 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
US10639294B2 (en) 2018-10-02 2020-05-05 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite
EP3920886A1 (en) * 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Taz activators and wnt agonists for treating ear disorders
US10993958B1 (en) * 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
CA3179583A1 (en) * 2020-04-06 2021-10-14 Humanetics Corporation Genistein treatment of inflammatory pulmonary injury
CA3184651A1 (en) * 2020-05-29 2021-12-02 Vedicinals India Private Limited A composition for management of covid-19 and associated disorders
US20230301959A1 (en) * 2020-07-01 2023-09-28 Deanna J. Nelson Combinations of carnosine and zinc for the treatment and prevention of viral infections
CN111643626A (zh) * 2020-07-21 2020-09-11 马良成 一种用于感冒、鼻炎、晕车的外用粉剂
JP2023536841A (ja) * 2020-07-27 2023-08-30 シーエイエス プロパティーズ リミテッド ライアビリティ カンパニー Ｃｏｖｉｄ－１９及び関連する病態の治療及び予防のためのノビレチン組成物ならびに方法
CN111920801A (zh) * 2020-09-18 2020-11-13 郑州大学第一附属医院 表没食子儿茶素没食子酸酯在制备治疗和/或预防埃克病毒感染所致疾病的药物中的用途
US20240009177A1 (en) * 2020-09-21 2024-01-11 Ramot At Tel-Aviv University Ltd. Combination compositions having anti-viral activities and uses thereof
CN114432288A (zh) * 2020-11-02 2022-05-06 苏州凯祥生物科技有限公司 黄酮类化合物在制备预防或治疗急性肺损伤或急性呼吸窘迫综合征的药物中用途
WO2022203547A1 (ru) * 2021-03-24 2022-09-29 Общество с ограниченной ответственностью "Научная Компания "Фламена" Применение фосфолипидной эмульсии для лечения гестозов первого триместра
RU2757360C1 (ru) * 2021-03-24 2021-10-14 Общество с ограниченной ответственностью "Научная Компания "Фламена" Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, лецитин и глицин для лечения воспалительных заболеваний органов дыхания
CN113384572A (zh) * 2021-06-11 2021-09-14 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 羟基芫花素在制备抗冠状病毒药物中的应用
US20220401403A1 (en) * 2021-06-14 2022-12-22 Global Biolife Inc. Method and composition for preventing and treating viral infections
US20230119141A1 (en) * 2021-10-19 2023-04-20 Phyto Tech Corp. Uses of taxifolin for respiratory health
CN113896702A (zh) * 2021-10-29 2022-01-07 晨光生物科技集团股份有限公司 一种槲皮万寿菊素-3-衍生物及用途
US11975009B2 (en) * 2022-05-02 2024-05-07 Znable Llc Use of zinc porphyrin as an antimicrobial

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH423808A (fr) * 1964-03-26 1966-11-15 Zyma Sa Procédé pour la préparation d'éthers O-B-hydroxyéthylés de la rutine
FR5072M (no) 1965-10-25 1967-05-16
US4956385A (en) * 1981-07-31 1990-09-11 Eby Iii George A Method for reducing the duration of the common cold
IE54795B1 (en) * 1982-04-29 1990-02-14 Efamol Ltd Pharmaceutical composition
WO1985003865A1 (en) * 1984-03-01 1985-09-12 Casley Smith John Royle Treatment of high protein oedemas in animals
EP0204987B1 (de) * 1985-05-15 1991-11-21 Roshdy Dr. Ismail Vitamin E-haltiges Mittel zur Verbesserung der Eigenschaften des Blutes
DE3603227A1 (de) * 1986-02-03 1987-08-20 Andreas Dipl Chem Ing D Vincze Pharmazeutische zubereitung, die als aktive substanz eine mischung von (+) catechin und ascorbolysinat enthaelt
JPH01501791A (ja) * 1986-11-19 1989-06-22 ケメックス　ファーマシューティカルズ，インコーポレイティド 薬理学的に活性な化合物およびそれらの混合物、有機組成物および金属塩類
KR890700023A (ko) * 1986-11-19 1989-03-02 케맥스 파마슈우티칼스 인코포레이티드 리폭시게나제 저해제
EP0396251A3 (en) 1989-03-31 1992-07-08 National University Of Singapore Use of fatty acids for the treatment of diseases associated with cytokines
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
EP0754450A1 (en) * 1990-10-16 1997-01-22 Mayor Pharmaceuticals Laboratories,Inc. Vitamin-mineral treatment methods and compositions
JPH04368331A (ja) 1991-06-17 1992-12-21 Nippon Oil & Fats Co Ltd 抗ｒｓウイルス剤
JPH08239319A (ja) * 1995-03-01 1996-09-17 Sanji Kumai 風邪予防トローチ
US5888527A (en) * 1995-05-11 1999-03-30 Matsushita Seiko Co., Ltd. Gargling cup, antiviral mask, antiviral filter, antifungal, antibacterial, and antiviral filter air cleaner and air-cleaner humidifier
US5649877A (en) * 1995-08-21 1997-07-22 Sram Corporation Linear derailleur
JPH0956333A (ja) 1995-08-21 1997-03-04 Kozaburo Shiba 機能性梅チョコレート
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
JPH09227373A (ja) 1996-02-21 1997-09-02 Teijin Ltd 抗インフルエンザウイルス剤
JP3585328B2 (ja) 1996-10-07 2004-11-04 株式会社エクセディ 粘性ダンパー機構
JPH10114653A (ja) * 1996-10-11 1998-05-06 Taishi Shokuhin Kogyo Kk 骨形成促進および骨塩量減少防止用組成物
US6013632A (en) * 1997-01-13 2000-01-11 Emory University Compounds and their combinations for the treatment of influenza infection
US5840278A (en) * 1997-02-20 1998-11-24 Coleman; Thomas Nasal spray having a mineral vitamin component, a mineral component and aloe vera
JP3202938B2 (ja) * 1997-03-18 2001-08-27 三井農林株式会社 チューインガム及びその製造法
US5834000A (en) 1997-04-11 1998-11-10 Yng-Wong; Quing Non Antiviral and antimicrobial herbal complex
AU2387997A (en) * 1997-04-18 1998-11-13 Klinge Pharma Gmbh Stabilized medicaments containing cysteinyl derivatives
JP4676040B2 (ja) * 1997-07-31 2011-04-27 株式会社林原生物化学研究所 組成物
US6224872B1 (en) * 1997-07-31 2001-05-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
CA2304763A1 (en) * 1997-09-29 1999-04-08 Pei Han A fagopyrum cymosum (trev.) meisn composition, method to prepare and analyze the same and uses thereof
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
JP2000327573A (ja) * 1999-05-18 2000-11-28 Taisho Pharmaceut Co Ltd 粘膜適用組成物
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
WO2001003681A2 (en) * 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
DE19949575A1 (de) * 1999-10-14 2001-04-19 Michael Hermann Hinz Neuartige Wirkstoffkombination von biologisch hochwirksamen Fluoriden u. Flavonoiden zur Therapie und Prphylaxe von Zahnerkrankungen
FI20000004A0 (fi) * 2000-01-03 2000-01-03 Slk Foundation Flavonoidilääke...
FR2822380B1 (fr) * 2001-03-23 2004-01-30 Oreal Utilisation d'un melange comprenant mn (ii) et/ou zn (ii) avec un hydrogenocarbonate et au moins un orthodiphenol, en tant qu'agent diminuant l'adhesion des micro-organismes

Also Published As

Publication number Publication date
WO2002009699A2 (en) 2002-02-07
NZ524121A (en) 2005-09-30
CN1466454A (zh) 2004-01-07
CN100411617C (zh) 2008-08-20
PL360140A1 (en) 2004-09-06
CA2416899C (en) 2010-10-12
AU2001279587B2 (en) 2006-08-17
ATE325612T1 (de) 2006-06-15
ES2263643T3 (es) 2006-12-16
DE60119534T2 (de) 2007-05-10
US20040053858A1 (en) 2004-03-18
US20050245467A1 (en) 2005-11-03
IL154144A (en) 2007-07-24
DE60119534D1 (de) 2006-06-14
CA2416899A1 (en) 2002-02-07
EP1307189A2 (en) 2003-05-07
PL203216B1 (pl) 2009-09-30
KR20030036648A (ko) 2003-05-09
KR100824075B1 (ko) 2008-04-22
US8003688B2 (en) 2011-08-23
HK1057330A1 (en) 2004-04-02
EA008612B1 (ru) 2007-06-29
WO2002009699A3 (en) 2003-01-03
EP1307189B1 (en) 2006-05-10
IL154144A0 (en) 2003-07-31
DK1307189T3 (da) 2006-09-18
BR0112818A (pt) 2004-10-19
NO20030337D0 (no) 2003-01-22
EA200300190A1 (ru) 2003-08-28
AU7958701A (en) 2002-02-13
JP2004505046A (ja) 2004-02-19
US7166640B2 (en) 2007-01-23
MXPA03000848A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
NO20030337L (no) Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber
MXPA04005865A (es) Suministro de aminoglucosidos a los pulmones.
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
PL375621A1 (en) Pharmaceutical compositions comprising flavonoids and menthol
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MY144616A (en) Substituted dihydroquinazolines
EE200300514A (et) Ftalasinoonid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ningneid sisaldavad ravimid
MY159377A (en) Aqueous suspensions of ciclesonide for nebulisation
EP1719515A3 (en) Glycyrrhizin or derivatives thereof for treating or preventing togavirus infections
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
WO2002007732A3 (en) Use of panaxatriol for stimulation angiogenesis
ES2134709A1 (es) Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m
WO2001076601A3 (en) Pharmaceutical compositions comprising salmeterol and ipratropium
BRPI0413054A (pt) combinação de um anticolinérgico e um esteróide e seu uso no tratamento de distúrbios respiratórios por inalação
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
MD20010417A (en) Antirecidivating method of treatment of rhinosinous polyposis associated with bronchial asthma
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
BRPI0414223A (pt) uso de extratos de gentiana lutea como um agente antimicrobiano
PT1150981E (pt) Composto nucleosidico terapeutico
MD2491F1 (en) Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment
BR0205625C1 (pt) Formulações nasais em gel
Leong The fifth disease [Erythema infectiosum]

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application